蓝图医药

BPMC NASDAQ
91.69
-1.13
-1.22%
盘后: 91.69 0 0.00% 18:07 06/25 EDT
开盘
92.00
昨收
92.82
最高
93.14
最低
89.18
成交量
58.68万
成交均量(3M)
52.97万
52周最高
100.76
52周最低
44.58
换手率
1.20%
市值
44.79亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供蓝图医药 BPMC股票价格,蓝图医药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.
展开 >

最近浏览

名称
价格
涨跌幅